Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Enhancing cancer immunotherapy with photodynamic therapy

<< Previous

Bullboard Posts

Next >>

Comment by wildbird1on Apr 22, 2024 11:01am

214 Views

Post# 36001328

RE:RE:Enhancing cancer immunotherapy with photodynamic therapy

Silly me,I forgot to include the link to prove my point.

In this link.... paragraph no 3...
https://cancer.gov/news-events/cancer-currents-blog/2019/immunotherapy-cancer-autoimmune-diseases-clinical-trial
It said...
'' Doctors have not know whether immunotherapy is safe and effective for people who have both cancer and autoimmune disease,because such patients heve been excluded from clinical trials of immunotherapy drugs''

Note:
Adstiladrin and CG0070(+Keytruda) are two exemples of immunotherapy drugs that have in their exclusions criteria '' Immunodeficients patients''.

TLT Ruvidar doesn't have this big exclusion criteria.
TLT-Ruvidar can treat 100% of patients ,including ''Immunodeficients patients''.

The above is just one more proof of TLT-Ruvidar impressive superiority.

wildbird1 wrote:
Oden6570 wrote: Frontiers | Enhancing cancer immunotherapy with photodynamic therapy and nanoparticle: making tumor microenvironment hotter to make immunotherapeutic work better (frontiersin.org)

Thank's Oden6570 very good link...

As we speak for safety purpose the FDA doesn't allow immunotherapy drugs to treat immunodeficients patients.
Combining Immunotherapy drugs with PDT could help resolve that situation.
But that is a long way to go,for now TLT must concentrate all it's efforts on getting NMIBC BTD approval.

Note; The above combination(immunotherapy + PDT) could be very interesting for a Big Pharma that use immunotherapy drugs(another long term plus-$value for TLT PDT).

Once TLT get the FDA-BTD approval and the money deal that come with it,the huge potential of TLT-PDT will be investigated.